Literature DB >> 27132507

FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism.

T Sewastianik1, M Szydlowski1, E Jablonska1, E Bialopiotrowicz1, P Kiliszek1, P Gorniak1, A Polak1, M Prochorec-Sobieszek1, A Szumera-Cieckiewicz1, T S Kaminski2, S Markowicz3, E Nowak3, M A Grygorowicz3, K Warzocha4, P Juszczynski1.   

Abstract

Molecular profiling has led to identification of subtypes of diffuse large B-cell lymphomas (DLBCLs) differing in terms of oncogenic signaling and metabolic programs. The OxPhos-DLBCL subtype is characterized by enhanced mitochondrial oxidative phosphorylation. As increased oxidative metabolism leads to overproduction of potentially toxic reactive oxygen species (ROS), we sought to identify mechanisms responsible for adaptation of OxPhos cells to these conditions. Herein, we describe a mechanism involving the FOXO1-TXN-p300 redox-dependent circuit protecting OxPhos-DLBCL cells from ROS toxicity. We identify a BCL6-dependent transcriptional mechanism leading to relative TXN overexpression in OxPhos cells. We found that OxPhos cells lacking TXN were uniformly more sensitive to ROS and doxorubicin than control cells. Consistent with this, the overall survival of patients with high TXN mRNA expression, treated with doxorubicin-containing regimens, is significantly shorter than of those with low TXN mRNA expression. TXN overexpression curtails p300-mediated FOXO1 acetylation and its nuclear translocation in response to oxidative stress, thus attenuating FOXO1 transcriptional activity toward genes involved in apoptosis and cell cycle inhibition. We also demonstrate that FOXO1 knockdown in cells with silenced TXN expression markedly reduces ROS-induced apoptosis, indicating that FOXO1 is the major sensor and effector of oxidative stress in OxPhos-DLBCLs. These data highlight dynamic, context-dependent modulation of FOXO1 tumor-suppressor functions via acetylation and reveal potentially targetable vulnerabilities in these DLBCLs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27132507     DOI: 10.1038/onc.2016.126

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

1.  Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas.

Authors:  Jose M Polo; Przemyslaw Juszczynski; Stefano Monti; Leandro Cerchietti; Kenny Ye; John M Greally; Margaret Shipp; Ari Melnick
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

Review 2.  The emerging roles of forkhead box (Fox) proteins in cancer.

Authors:  Stephen S Myatt; Eric W-F Lam
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

3.  BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate.

Authors:  Przemyslaw Juszczynski; Jeffery L Kutok; Cheng Li; Joydeep Mitra; Ricardo C T Aguiar; Margaret A Shipp
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

4.  Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.

Authors:  Stefano Monti; Kerry J Savage; Jeffery L Kutok; Friedrich Feuerhake; Paul Kurtin; Martin Mihm; Bingyan Wu; Laura Pasqualucci; Donna Neuberg; Ricardo C T Aguiar; Paola Dal Cin; Christine Ladd; Geraldine S Pinkus; Gilles Salles; Nancy Lee Harris; Riccardo Dalla-Favera; Thomas M Habermann; Jon C Aster; Todd R Golub; Margaret A Shipp
Journal:  Blood       Date:  2004-11-18       Impact factor: 22.113

5.  The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells.

Authors:  Ryan T Phan; Riccardo Dalla-Favera
Journal:  Nature       Date:  2004-12-02       Impact factor: 49.962

6.  Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma.

Authors:  Pilar Caro; Amar U Kishan; Erik Norberg; Illana A Stanley; Bjoern Chapuy; Scott B Ficarro; Klaudia Polak; Daniel Tondera; John Gounarides; Hong Yin; Feng Zhou; Michael R Green; Linfeng Chen; Stefano Monti; Jarrod A Marto; Margaret A Shipp; Nika N Danial
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

7.  Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity.

Authors:  Hiroaki Daitoku; Mitsutoki Hatta; Hitomi Matsuzaki; Satoko Aratani; Takayuki Ohshima; Makoto Miyagishi; Toshihiro Nakajima; Akiyoshi Fukamizu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-25       Impact factor: 11.205

8.  FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.

Authors:  Maciej Szydlowski; Przemyslaw Kiliszek; Tomasz Sewastianik; Ewa Jablonska; Emilia Bialopiotrowicz; Patryk Gorniak; Anna Polak; Sergiusz Markowicz; Eliza Nowak; Monika A Grygorowicz; Monika Prochorec-Sobieszek; Anna Szumera-Cieckiewicz; Agata Malenda; Ewa Lech-Maranda; Krzysztof Warzocha; Przemyslaw Juszczynski
Journal:  Blood       Date:  2015-11-19       Impact factor: 22.113

9.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma.

Authors:  Laura Pasqualucci; David Dominguez-Sola; Annalisa Chiarenza; Giulia Fabbri; Adina Grunn; Vladimir Trifonov; Lawryn H Kasper; Stephanie Lerach; Hongyan Tang; Jing Ma; Davide Rossi; Amy Chadburn; Vundavalli V Murty; Charles G Mullighan; Gianluca Gaidano; Raul Rabadan; Paul K Brindle; Riccardo Dalla-Favera
Journal:  Nature       Date:  2011-03-10       Impact factor: 49.962

10.  Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma.

Authors:  Changping Li; Michael A Thompson; Archito T Tamayo; Zhuang Zuo; John Lee; Francisco Vega; Richard J Ford; Lan V Pham
Journal:  Oncotarget       Date:  2012-03
View more
  12 in total

1.  A Mutation in Endogenous saRNA miR-23a Influences Granulosa Cells Response to Oxidative Stress.

Authors:  Siqi Wang; Yuqi Li; Qiang Zeng; Liu Yang; Xing Du; Qifa Li
Journal:  Antioxidants (Basel)       Date:  2022-06-15

Review 2.  Heart Failure in Type 2 Diabetes Mellitus.

Authors:  Helena C Kenny; E Dale Abel
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

Review 3.  Redox regulation of the insulin signalling pathway.

Authors:  Claudia Lennicke; Helena M Cochemé
Journal:  Redox Biol       Date:  2021-04-02       Impact factor: 11.799

Review 4.  New insights into redox homeostasis as a therapeutic target in B-cell malignancies.

Authors:  Agnieszka Graczyk-Jarzynka; Radoslaw Zagozdzon; Angelika Muchowicz; Marta Siernicka; Przemyslaw Juszczynski; Malgorzata Firczuk
Journal:  Curr Opin Hematol       Date:  2017-07       Impact factor: 3.284

5.  Estradiol Suppresses TLR4-triggered Apoptosis of Decidual Stromal Cells and Drives an Anti-inflammatory TH2 Shift by Activating SGK1.

Authors:  Yiyun Lou; Minhao Hu; Qijing Wang; Mu Yuan; Ning Wang; Fang Le; Lejun Li; Shisi Huang; Liya Wang; Xiangrong Xu; Fan Jin
Journal:  Int J Biol Sci       Date:  2017-03-11       Impact factor: 6.580

6.  Transcriptional repression of FOXO1 by KLF4 contributes to glioma progression.

Authors:  Guodong Tang; Dingyang Liu; Gelei Xiao; Qing Liu; Jian Yuan
Journal:  Oncotarget       Date:  2016-12-06

7.  Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2.

Authors:  Heike Horn; Christian Kohler; Raphael Witzig; Markus Kreuz; Ellen Leich; Wolfram Klapper; Michael Hummel; Markus Loeffler; Lorenz Trümper; Rainer Spang; Andreas Rosenwald; German Ott
Journal:  Haematologica       Date:  2018-03-22       Impact factor: 9.941

8.  Targeting the thioredoxin system as a novel strategy against B-cell acute lymphoblastic leukemia.

Authors:  Klaudyna Fidyt; Agata Pastorczak; Agnieszka Goral; Kacper Szczygiel; Wojciech Fendler; Angelika Muchowicz; Marcin Adam Bartlomiejczyk; Joanna Madzio; Julia Cyran; Agnieszka Graczyk-Jarzynka; Eugene Jansen; Elzbieta Patkowska; Ewa Lech-Maranda; Deepali Pal; Helen Blair; Anna Burdzinska; Piotr Pedzisz; Eliza Glodkowska-Mrowka; Urszula Demkow; Karolina Gawle-Krawczyk; Michal Matysiak; Magdalena Winiarska; Przemyslaw Juszczynski; Wojciech Mlynarski; Olaf Heidenreich; Jakub Golab; Malgorzata Firczuk
Journal:  Mol Oncol       Date:  2019-04-05       Impact factor: 6.603

Review 9.  cROSsing the Line: Between Beneficial and Harmful Effects of Reactive Oxygen Species in B-Cell Malignancies.

Authors:  Krzysztof Domka; Agnieszka Goral; Malgorzata Firczuk
Journal:  Front Immunol       Date:  2020-07-21       Impact factor: 7.561

10.  SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.

Authors:  Anna Polak; Emilia Bialopiotrowicz; Beata Krzymieniewska; Jolanta Wozniak; Marta Stojak; Magdalena Cybulska; Ewelina Kaniuga; Michał Mikula; Ewa Jablonska; Patryk Gorniak; Monika Noyszewska-Kania; Maciej Szydlowski; Karolina Piechna; Katarzyna Piwocka; Lukasz Bugajski; Ewa Lech-Maranda; Joanna Barankiewicz; Agnieszka Kolkowska-Lesniak; Elzbieta Patkowska; Eliza Glodkowska-Mrowka; Natalia Baran; Przemyslaw Juszczynski
Journal:  Cell Death Dis       Date:  2020-11-06       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.